Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with Rifampicin
Aida N. Kawuma, Roeland E. Wasmann, Kelly E. Dooley, Marta Boffito, Gary Maartens, Paolo Denti
Abstract
), respectively. The model developed from healthy-volunteer data describes patient data reasonably well but underpredicts trough concentrations. Although 50 mg of dolutegravir given twice daily achieves target concentrations in more than 99% of individuals cotreated with rifampicin, 100 mg of dolutegravir, once daily, in the same population is predicted to achieve satisfactory pharmacokinetic target attainment. The efficacy of this regimen should be investigated since it presents an opportunity for treatment simplification.
Topics & Concepts
DolutegravirPharmacokineticsNONMEMMedicinePharmacologyPopulationDosingPharmacodynamicsRifapentineRifampicinLatent tuberculosisTuberculosisVirologyHuman immunodeficiency virus (HIV)Viral loadAntiretroviral therapyMycobacterium tuberculosisPathologyEnvironmental healthHIV/AIDS drug development and treatmentPharmacological Effects and Toxicity StudiesDrug Transport and Resistance Mechanisms